Company intelligence / Profile preview

Nanocan Therapeutics Corporation

Princeton, New Jersey, United States

Ownership: Private
Employees: ~5
Development stage: Preclinical

Overview

Nanocan has developed a novel drug delivery platform called NEST™ that enables immune-modulating agents to work more effectively by locating and releasing active therapeutics in the tumor microenvironment. The company has preclinical data showing promising results for pancreatic cancer treatment.[1][3]

Therapeutic areas: Oncology
Modalities: Nanotechnology-based drug delivery
Industry: Biotech

Partnerships

Partnerships with leading US and UK universities

Beyond the preview

Go deeper on Nanocan Therapeutics Corporation.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Nanocan Therapeutics Corporation.

Explore the full profile